


average skill to activate/reactivate the action of conductin in the body for the treatment of tumor diseases.

The Office action rejected claims 33-34 under 35 U.S.C. 102(b) as being anticipated by Behrens et al., Science, 1998, Vol. 280(24):596-599, ("Behrens"). Applicants respectfully traverse.

The present application claims priority to German patent application no. 197 38 205.3 filed on September 2, 1997 as detailed in the Declaration with Power submitted with the present application. The cited Behrens article was published April 24, 1998, more than 7 months after the filing of the priority application. ✓


In view of the foregoing, reconsideration of the outstanding rejections, and the allowance of claims 33-34, are respectfully urged.


Respectfully submitted,

  
\_\_\_\_\_  
Gabriel P. Katona  
Attorney of Record

GOODWIN PROCTER L.L.P.  
599 Lexington Avenue  
New York, NY 10022  
Tel: (212) 813-8800  
Fax: (212) 355-3333  
Enclosures

It is hereby certified that this is being mailed,  
as addressed above, on February 14, 2002.

  
\_\_\_\_\_  
Francene Sawyer



COMPARISON COPY OF CLAIM AMENDMENTS

33. Substantially pure [C]conductin[e], its variations, mutants and parts thereof.

34. The substantially pure conductin[e] of claim 33 of the amino acid sequence 1 to 840 of Sequence ID No. 1 and Fig. 1.